Prognostic Value of Vascular Endothelial Growth Factor A in the Prediction of the Tumor Aggressiveness in Clear Cell Renal Cell Carcinoma

Fahredin Veselaj; Suzana Manxhuka-Kerliu; Arber Neziri; Labinot Shahini; Shefki Xharra; Liridon Selmani; Lloreta Kerliu; Floren Kavaja

doi:10.3889/oamjms.2017.035

Authors

Fahredin Veselaj University Clinical Centre of Kosovo, Clinic of Urology, Prishtina, Kosovo
Suzana Manxhuka-Kerliu Department of Pathology, UCC of Kosovo, Prishtina, Kosovo
Arber Neziri University Clinical Centre of Kosovo, Clinic of Urology, Prishtina, Kosovo
Labinot Shahini Department of Pathology, UCC of Kosovo, Prishtina, Kosovo
Shefki Xharra Regional Hospital, Prizren, Kosovo
Liridon Selmani University Clinical Centre of Kosovo, Clinic of Urology, Prishtina, Kosovo
Lloreta Kerliu Massachusetts College of Pharmacy and Health Sciences (MCPHS), 179 Longwood Avenue, Boston, MA 02115
Floren Kavaja Clinic of Surgery, UCC of Kosovo, Prishtina, Kosovo

DOI:

https://doi.org/10.3889/oamjms.2017.035

Keywords:

Clear cell RCC, Angiogenesis, VEGF-A, prognostic factors

Abstract

BACKGROUND: Clear cell renal cell carcinoma (CCRCC) is the most predominant renal tumour with unpredictable tumour behaviour. The aim of the study is to investigate the prognostic value of vascular endothelial growth factor A (VEGF-A) expression in CCRCC and to correlate it with other histological parameters as well as with patient's survival.

MATERIAL AND METHODS: Tumour blocks were taken from 40 patients with histopathology diagnosis of CCRCC and tissue block from 20 normal kidneys as a control group were examined using the immuno-histochemical staining for VEGF-A.

RESULTS: The VEGF A expression in CCRCC was significantly higher than in the normal kidney tissues (Uâ€™ = 720, P < 0.0001). VEGF A expression values in CCRCC were positively correlated with Disease Free Survival (r = 0.335, P = 0.034) and the tumor necrosis degree (r = 0.181, P = 0.262). VEGF-A expression values in CCRCC did not correlate with CD 31 expression (r = -0.09, P = 0.549), and Progression Free Survival (r = -0.07, P = 0.838). VEGF A expression values in CCRCC were negatively correlated with the tumor nuclear grade (r = -0.161, P = 0.318); the pathological tumor stage (r = -0.371, P = 0.018); the tumor size (r = -0.361, P = 0.022); the degree of tumor hemorrhage (r = -0.235, P = 0.143); and Cancer Specific SurvivalÂ Â (r = -0.207, P = 0.713).

CONCLUSIONS: VEGF-A expression can be used to stratify advanced and metastatic CCRCC patients into low-benefit and high-benefit groups. Based on this study outcome it would be useful to perform IHC staining for VEGF-A expression in all patients with advanced and metastatic CCRCC.

Downloads

Download data is not yet available.

Metrics

Metrics Loading ...

Plum Analytics Artifact Widget Block

References

Jemal A, Siegel R, Ward E, et al. Cancer statistics, 2008. CA Cancer J Clin. 2008; 58: 71â€“96. https://doi.org/10.3322/CA.2007.0010 PMid:18287387

Socialstyrelsen: Cancer Incidence in Sweden 2003. The National Board of Health and Welfare, Centre for Epidemiology, 2004.

Yagoda A. (1990) Phase II cytotoxic chemotherapy trials in renal cell carcinoma: 1983â€“1988. Prog Clin Biol Res. 1990;350:227â€“241. PMid:2201045

Yoshino S, Kato M. and Okada K. Clinical significance of angiogenesis, proliferation and apoptosis in renal cell carcinoma. Anticancer Res. 2000; 20:591â€“594. PMid:10769700

Cockerill GW, Gamble JR, Vadas MA. Angiogenesis: models and modulators. Int Rev Cytol. 1995; 159:113â€“60. https://doi.org/10.1016/S0074-7696(08)62106-3

Ferrara N, Davis ST. The biology of vascular endothelial growth factor. Endocr Rev. 1997;18: 4â€“25. https://doi.org/10.1210/edrv.18.1.0287 PMid:9034784

Senger DR, Connolly DT, Van de Water L, Feder J, Dvorak HF. Purification and NH2-terminal amino acid sequence of guinea pig tumor-secreted vascular permeability factor. Cancer Res. 1990; 50:1774â€“1778. PMid:2155059

Leung DW, Cachianes G, Kuang WJ, Goeddel DV, Ferrara N. Vascular endothelial growth factor is a secreted angiogenic mitogen. Science. 1989; 246:1306â€“1309. https://doi.org/10.1126/science.2479986 PMid:2479986

Shweiki D, Itin A, Soffer D, Keshet E. Vascular endothelial growth factor induced by hypoxia may mediate hypoxia-initiated angiogenesis. Nature. 1992; 359:843â€“845. https://doi.org/10.1038/359843a0 PMid:1279431

Frank S, Hubner G, Breier G, Longaker MT, Greenhalgh DG, Werner S. Regulation of vascular endothelial growth factor expression in cultured keratinocytes. Implications for normal and impaired wound healing. J Biol Chem. 1995; 270:12607â€“12613. https://doi.org/10.1074/jbc.270.21.12607 PMid:7759509

Takahashi H, Shibuya M. The vascular endothelial growth factor (VEGF)/VEGF receptor system and its role under physiological and pathological conditions. Clin Sci (Lond). 2005; 109:227â€“241. https://doi.org/10.1042/CS20040370 PMid:16104843

Fuhrman SA, Lasky LC, Limas C. Prognostic significance of morphologic parameters in renal cell carcinoma. Am J Surg Pathol. 1982;6: 655-663. https://doi.org/10.1097/00000478-198210000-00007 PMid:7180965

Edge SB, Byrd DR, Compton CC, et al. AJCC Cancer Staging Manual. 7th ed. New York, NY: Springer, 2011: 479-89.

Sang HS. In Gab J, Dalsan Y, et al. VEGF/VEGFR2 and PDGF-B/PDGFR-Î² expression in non-metastatic renal cell carcinoma: a retrospective study in 1,091 consecutive patients. Int J Clin Exp Pathol. 2014; 7(11):7681-7689.

Weidner N, Semple JP, Welch WR, Folkman J. Tumor angiogenesis and metastasis-correlation in invasive breast carcinoma. N Engl J Med. 1991; 324:1â€“8. https://doi.org/10.1056/NEJM199101033240101 PMid:1701519

Takano S, Yoshii Y, Kondo S, Suzuki H, Maruno T, Shirai S, Nose T. Concentration of vascular endothelial growth factor in the serum and tumor tissue of brain tumor patients. Cancer Res. 1996:2185â€“2190. PMid:8616870

Ferrara N, Henzel WJ. Pituitary follicular cells secrete a novel heparin-binding growth factor specific for vascular endothelial cells. Biochem Biophys Res Commun. 1989; 161:851â€“8. https://doi.org/10.1016/0006-291X(89)92678-8

Weidner N. Intratumor microvessel density as a prognostic factor in cancer. Am J Pathol. 1995; 147: 9â€“19. PMid:7541613 PMCid:PMC1869874

Yoshino S, Kato M, Okada K. Evaluation of the prognostic significance of microvessel count and tumor size in renal cell carcinoma. Int J Urol. 1998; 5:119â€“23. https://doi.org/10.1111/j.1442-2042.1998.tb00258.x PMid:9559835

Rioux-Leclercq N, Fergelot P, Zerrouki S, Leray E, Jouan F, Bellaud P, Epstein JI, Patard JJ. Plasma level and tissue expression of vascular endothelial growth factor in renal cell carcinoma: a prospective study of 50 cases. Human Pathology. 2007; 38(10):1489-1495. https://doi.org/10.1016/j.humpath.2007.02.014 PMid:17597181

Paradis V, Lagha NB, Zeimoura L, Blanchet P, Eschwege P, Ba N, BenoÃ®t G, Jardin A, Bedossa P. Expression of vascular endothelial growth factor in renal cell carcinomas. Virchows Arch. 2000; 436: 351-356. https://doi.org/10.1007/s004280050458 PMid:10834538

Yildiz E, Gokce G, Kilicarslan H, Ayan S, Goze OF, Gultekin EY. Prognostic value of the expression of Ki-67, CD44 and vascular endothelial growth factor, and microvessel invasion, in renal cell carcinoma. BJU Int. 2004; 93: 1087-1093. https://doi.org/10.1111/j.1464-410X.2004.04786.x PMid:15142169

Nativ O, Sabo E, Reiss A, Wald M, Madjar S, Moskovitz B. Clinical significance of tumor angiogenesis in patients with localized renal cell carcinoma. Urology. 1998; 51: 693â€“6. https://doi.org/10.1016/S0090-4295(98)00019-3

Kohler HH, Barth PJ, Siebel A, Gerharz EW, Bittinger A. Quantitative assessment of vascular surface density in renal cell carcinomas. Br J Urol. 1996; 77: 650â€“4. https://doi.org/10.1046/j.1464-410X.1996.08544.x PMid:8689104

Verheul HM, van Erp K, Homs MY, Yoon GS, van der Groep P, Rogers C, Hansel DE, Netto GJ, Pili R. The relationship of vascular endothelial growth factor and coagulation factor (fibrin and fibrinogen) expression in clear cell renal cell carcinoma. Urology. 2010; 75:608-614. https://doi.org/10.1016/j.urology.2009.05.075 PMid:19683801

Minardi, G. Lucarini, G. Milanese et al. Tumor necrosis, microvessel density growth factor and hypoxia inducible factor -1Î± in patients with Clear Cell Renal Carcinoma after radical nephrectomy in a long term follow-upd. Internation Journal of Immunopathology and Pharmacology. 2008; 21(2):0394-6320.

Djordjevica G, Mozetic V, Vrdoljakâ€“Mozetic D, et al. Prognostic significance of vascular endothelial growth factor expression in clear cell renal cell carcinoma. Pathologyâ€“Research and Practice. 2007; 203:99â€“106. https://doi.org/10.1016/j.prp.2006.12.002 PMid:17270362

Jacobsen J, Rasmuson T, Grankvist K, Ljungberg B. Vascular endothelial growth factor as prognostic factor in renal cellcarcinoma. Journal of Urology. 2000; 163(1): 343-7. https://doi.org/10.1016/S0022-5347(05)68049-4

Jacobsen J, Grankvist K, Rasmuson T, Bergh A, Landberg G, Ljungberg B. Expression of vascular endothelial growth factor protein in human renal cell carcinoma. BJU Int. 2004; 93(3):297-302. https://doi.org/10.1111/j.1464-410X.2004.04605.x PMid:14764126